<DOC>
	<DOCNO>NCT00623012</DOCNO>
	<brief_summary>The objective study evaluate feasibility , toxicity efficacy use Rapamycin prevent chronic graft-versus-host-disease ( GVHD ) tacrolimus taper recipient allogeneic stem cell transplant . Our hypothesis T cell cause chronic GVHD suppress eliminate calcineurin inhibitor . Therefore , calcineurin inhibitor discontinue , T cell may get activated result GVHD . Rapamycin hand allow anergy formation thus discontinue , T cell get activate . The schedule design therapeutic rapamycin level tacrolimus discontinue . Rapamycin continue single agent additional 4 week taper two week .</brief_summary>
	<brief_title>Rapamycin Prevention Chronic Graft-Versus-Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age â‰¥18 year Received allogeneic MSD MUD PBSCT 24 week post SCT Currently Tacrolimus GVHD prophylaxis Deemed eligible taper Tacrolimus primary BMT physician Relapsed Disease Ongoing GVHD Patients whose immunosuppression stop early treat prevent relapse Patients pure red cell aplasia due ABO mismatch donor Ongoing thrombotic microangiopathy Allergy rapamycin Women childbearing potential must negative serum pregnancy test perform prior start treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>